| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macaca fascicularis | 47 | 2021 | 397 | 4.360 |
Why?
|
| Postmenopause | 22 | 2019 | 413 | 3.700 |
Why?
|
| Ovarian Follicle | 7 | 2014 | 29 | 2.180 |
Why?
|
| Ovary | 10 | 2016 | 58 | 2.100 |
Why?
|
| Coronary Artery Disease | 9 | 2015 | 398 | 1.760 |
Why?
|
| Estrogens, Conjugated (USP) | 6 | 2014 | 128 | 1.710 |
Why?
|
| Animals | 73 | 2021 | 7450 | 1.680 |
Why?
|
| Atherosclerosis | 13 | 2019 | 767 | 1.680 |
Why?
|
| Isoflavones | 15 | 2015 | 68 | 1.540 |
Why?
|
| Soybean Proteins | 11 | 2015 | 67 | 1.500 |
Why?
|
| Ovariectomy | 20 | 2018 | 149 | 1.410 |
Why?
|
| Estrogens | 6 | 2016 | 167 | 1.330 |
Why?
|
| Coronary Vessels | 6 | 2015 | 158 | 1.260 |
Why?
|
| Menopause | 8 | 2014 | 92 | 1.260 |
Why?
|
| Premenopause | 9 | 2019 | 42 | 1.220 |
Why?
|
| Anti-Mullerian Hormone | 7 | 2017 | 15 | 1.210 |
Why?
|
| Estradiol | 15 | 2018 | 128 | 1.180 |
Why?
|
| Female | 74 | 2021 | 19859 | 1.110 |
Why?
|
| Indoles | 4 | 2014 | 56 | 1.100 |
Why?
|
| Estrogen Replacement Therapy | 5 | 2013 | 187 | 1.090 |
Why?
|
| Vinyl Compounds | 4 | 2010 | 8 | 1.020 |
Why?
|
| Models, Animal | 10 | 2016 | 164 | 0.980 |
Why?
|
| Perimenopause | 3 | 2015 | 13 | 0.940 |
Why?
|
| Receptors, Calcitriol | 2 | 2012 | 9 | 0.840 |
Why?
|
| Cyclohexenes | 4 | 2010 | 12 | 0.810 |
Why?
|
| Corpus Luteum | 3 | 2016 | 4 | 0.790 |
Why?
|
| Selective Estrogen Receptor Modulators | 4 | 2014 | 34 | 0.790 |
Why?
|
| Lipids | 9 | 2019 | 228 | 0.750 |
Why?
|
| Diet, Atherogenic | 10 | 2015 | 61 | 0.720 |
Why?
|
| Aging | 5 | 2017 | 941 | 0.710 |
Why?
|
| Disease Models, Animal | 14 | 2021 | 1012 | 0.690 |
Why?
|
| Menstrual Cycle | 3 | 2018 | 59 | 0.690 |
Why?
|
| Diet, Mediterranean | 4 | 2021 | 31 | 0.680 |
Why?
|
| Carotid Artery Diseases | 3 | 2017 | 114 | 0.670 |
Why?
|
| Iliac Artery | 8 | 2015 | 49 | 0.660 |
Why?
|
| Weight Gain | 2 | 2016 | 116 | 0.630 |
Why?
|
| Cholecalciferol | 3 | 2012 | 20 | 0.620 |
Why?
|
| Diet | 9 | 2021 | 385 | 0.560 |
Why?
|
| Biogenic Amines | 1 | 2016 | 1 | 0.560 |
Why?
|
| Carnitine | 1 | 2016 | 14 | 0.560 |
Why?
|
| Haplorhini | 10 | 2019 | 66 | 0.550 |
Why?
|
| Norpregnenes | 4 | 2008 | 16 | 0.550 |
Why?
|
| Sertraline | 4 | 2017 | 27 | 0.550 |
Why?
|
| Estrogen Receptor Modulators | 4 | 2008 | 25 | 0.550 |
Why?
|
| Metabolome | 1 | 2016 | 36 | 0.550 |
Why?
|
| Amino Acids | 1 | 2016 | 46 | 0.540 |
Why?
|
| Dietary Supplements | 4 | 2015 | 185 | 0.530 |
Why?
|
| Cardiovascular Diseases | 4 | 2015 | 1122 | 0.520 |
Why?
|
| C-Reactive Protein | 3 | 2012 | 239 | 0.490 |
Why?
|
| Vitamin D | 2 | 2015 | 183 | 0.490 |
Why?
|
| Vitamin D Deficiency | 1 | 2015 | 89 | 0.480 |
Why?
|
| Reproduction | 1 | 2014 | 12 | 0.470 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2014 | 12 | 0.460 |
Why?
|
| Endometriosis | 3 | 2019 | 98 | 0.430 |
Why?
|
| Calcifediol | 1 | 2012 | 7 | 0.430 |
Why?
|
| Weight Loss | 1 | 2016 | 465 | 0.430 |
Why?
|
| Vitamin K 2 | 1 | 2012 | 1 | 0.420 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2010 | 27 | 0.420 |
Why?
|
| Energy Metabolism | 3 | 2019 | 148 | 0.400 |
Why?
|
| Vitamins | 1 | 2012 | 68 | 0.400 |
Why?
|
| Cytochromes b5 | 1 | 2011 | 2 | 0.400 |
Why?
|
| 3-Hydroxysteroid Dehydrogenases | 1 | 2011 | 2 | 0.400 |
Why?
|
| Choristoma | 1 | 2011 | 16 | 0.400 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2011 | 3 | 0.400 |
Why?
|
| Lactalbumin | 2 | 2014 | 10 | 0.400 |
Why?
|
| Caseins | 2 | 2014 | 14 | 0.400 |
Why?
|
| Random Allocation | 8 | 2018 | 218 | 0.400 |
Why?
|
| Theca Cells | 1 | 2011 | 9 | 0.400 |
Why?
|
| Gene Expression | 7 | 2021 | 334 | 0.390 |
Why?
|
| Androgens | 1 | 2011 | 29 | 0.390 |
Why?
|
| Bone Density | 2 | 2012 | 194 | 0.390 |
Why?
|
| Macaca mulatta | 7 | 2019 | 285 | 0.390 |
Why?
|
| Primates | 6 | 2021 | 104 | 0.370 |
Why?
|
| Sexual Development | 1 | 2010 | 3 | 0.370 |
Why?
|
| Ovarian Diseases | 1 | 2010 | 8 | 0.370 |
Why?
|
| Arteries | 4 | 2019 | 67 | 0.360 |
Why?
|
| Breast Neoplasms | 6 | 2019 | 760 | 0.360 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2012 | 629 | 0.350 |
Why?
|
| Phytoestrogens | 5 | 2013 | 17 | 0.340 |
Why?
|
| Carcinogens | 1 | 2009 | 33 | 0.330 |
Why?
|
| Hyperlipoproteinemias | 1 | 2008 | 1 | 0.320 |
Why?
|
| Energy Intake | 2 | 2019 | 126 | 0.320 |
Why?
|
| Chronic Disease | 1 | 2010 | 400 | 0.320 |
Why?
|
| Peer Review, Research | 1 | 2008 | 9 | 0.310 |
Why?
|
| Soybeans | 4 | 2014 | 26 | 0.310 |
Why?
|
| Serotonin Uptake Inhibitors | 3 | 2017 | 37 | 0.300 |
Why?
|
| Apoptosis | 1 | 2009 | 354 | 0.280 |
Why?
|
| Cyclohexanes | 1 | 2006 | 4 | 0.280 |
Why?
|
| Time Factors | 7 | 2018 | 2146 | 0.280 |
Why?
|
| Mammary Glands, Animal | 4 | 2012 | 47 | 0.270 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2015 | 504 | 0.260 |
Why?
|
| Models, Biological | 3 | 2016 | 391 | 0.250 |
Why?
|
| Soy Foods | 2 | 2006 | 6 | 0.250 |
Why?
|
| Depression | 3 | 2017 | 442 | 0.250 |
Why?
|
| Endometrium | 4 | 2019 | 175 | 0.240 |
Why?
|
| Humans | 20 | 2021 | 31836 | 0.240 |
Why?
|
| Fatty Acids | 3 | 2019 | 97 | 0.240 |
Why?
|
| Immunohistochemistry | 4 | 2016 | 531 | 0.230 |
Why?
|
| Injections, Intramuscular | 3 | 2009 | 41 | 0.230 |
Why?
|
| Arteriosclerosis | 1 | 2003 | 122 | 0.220 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2003 | 93 | 0.220 |
Why?
|
| Bone and Bones | 1 | 2004 | 91 | 0.220 |
Why?
|
| Follicle Stimulating Hormone | 2 | 2014 | 28 | 0.220 |
Why?
|
| Obesity | 4 | 2021 | 1158 | 0.210 |
Why?
|
| Body Weight | 4 | 2016 | 306 | 0.210 |
Why?
|
| Risk Factors | 6 | 2017 | 3851 | 0.200 |
Why?
|
| Social Behavior | 1 | 2021 | 65 | 0.190 |
Why?
|
| Cholesterol | 2 | 2018 | 251 | 0.190 |
Why?
|
| Inflammation | 3 | 2021 | 540 | 0.190 |
Why?
|
| Progesterone | 3 | 2016 | 95 | 0.180 |
Why?
|
| Muscle, Skeletal | 2 | 2019 | 513 | 0.180 |
Why?
|
| Apolipoproteins E | 2 | 2018 | 94 | 0.180 |
Why?
|
| Antidepressive Agents | 2 | 2017 | 74 | 0.180 |
Why?
|
| Monocytes | 1 | 2021 | 126 | 0.180 |
Why?
|
| Longitudinal Studies | 4 | 2017 | 771 | 0.170 |
Why?
|
| Helicobacter pylori | 1 | 2019 | 6 | 0.170 |
Why?
|
| Helicobacter Infections | 1 | 2019 | 8 | 0.170 |
Why?
|
| Mitochondria | 2 | 2019 | 186 | 0.170 |
Why?
|
| Mitochondria, Muscle | 1 | 2019 | 18 | 0.170 |
Why?
|
| Doxorubicin | 1 | 2019 | 82 | 0.170 |
Why?
|
| Hippocampus | 2 | 2011 | 171 | 0.170 |
Why?
|
| Peptides | 2 | 2018 | 119 | 0.170 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2019 | 74 | 0.170 |
Why?
|
| Mammary Glands, Human | 1 | 2018 | 15 | 0.160 |
Why?
|
| Fatty Liver | 1 | 2019 | 65 | 0.160 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2019 | 169 | 0.160 |
Why?
|
| Diastole | 1 | 2018 | 96 | 0.160 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2019 | 120 | 0.160 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2018 | 9 | 0.160 |
Why?
|
| Homeostasis | 1 | 2018 | 132 | 0.150 |
Why?
|
| Body Composition | 2 | 2019 | 388 | 0.150 |
Why?
|
| Cell Proliferation | 5 | 2015 | 598 | 0.150 |
Why?
|
| Receptors, Estrogen | 2 | 2016 | 103 | 0.150 |
Why?
|
| Carotid Artery, Common | 1 | 2017 | 39 | 0.150 |
Why?
|
| Iron | 1 | 2018 | 115 | 0.150 |
Why?
|
| Dietary Fats | 2 | 2015 | 110 | 0.150 |
Why?
|
| Heart | 1 | 2018 | 178 | 0.150 |
Why?
|
| Hyperandrogenism | 1 | 2017 | 2 | 0.150 |
Why?
|
| Gene Expression Regulation | 3 | 2016 | 493 | 0.150 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2017 | 20 | 0.140 |
Why?
|
| Calcium | 1 | 2018 | 304 | 0.140 |
Why?
|
| Extracellular Matrix | 1 | 2018 | 245 | 0.140 |
Why?
|
| Monkey Diseases | 1 | 2016 | 16 | 0.140 |
Why?
|
| Decidua | 1 | 2016 | 18 | 0.140 |
Why?
|
| Hormones | 1 | 2016 | 21 | 0.140 |
Why?
|
| Middle Aged | 6 | 2015 | 11824 | 0.140 |
Why?
|
| Metabolomics | 1 | 2016 | 52 | 0.130 |
Why?
|
| Infertility, Female | 1 | 2016 | 37 | 0.130 |
Why?
|
| RNA, Messenger | 2 | 2015 | 508 | 0.130 |
Why?
|
| Granulosa Cells | 1 | 2015 | 11 | 0.130 |
Why?
|
| Neovascularization, Physiologic | 1 | 2016 | 110 | 0.130 |
Why?
|
| Androstenedione | 2 | 2017 | 5 | 0.130 |
Why?
|
| Retrospective Studies | 2 | 2016 | 3488 | 0.130 |
Why?
|
| Blood Glucose | 2 | 2019 | 491 | 0.120 |
Why?
|
| Thyroid Hormones | 1 | 2014 | 5 | 0.120 |
Why?
|
| Lipoproteins | 2 | 2006 | 84 | 0.120 |
Why?
|
| Depressive Disorder | 1 | 2015 | 75 | 0.120 |
Why?
|
| Menstruation | 1 | 2014 | 5 | 0.120 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 323 | 0.120 |
Why?
|
| Cross-Over Studies | 3 | 2008 | 93 | 0.120 |
Why?
|
| Basilar Artery | 1 | 2014 | 9 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2010 | 912 | 0.120 |
Why?
|
| Luteinizing Hormone | 1 | 2013 | 22 | 0.110 |
Why?
|
| Drug Combinations | 1 | 2014 | 93 | 0.110 |
Why?
|
| Coronary Disease | 1 | 2015 | 213 | 0.110 |
Why?
|
| Carotid Artery, Internal | 1 | 2014 | 32 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 1323 | 0.110 |
Why?
|
| Behavior, Animal | 1 | 2015 | 250 | 0.110 |
Why?
|
| Women's Health | 2 | 2013 | 235 | 0.110 |
Why?
|
| Bone Density Conservation Agents | 1 | 2013 | 21 | 0.110 |
Why?
|
| Drug Interactions | 1 | 2013 | 79 | 0.110 |
Why?
|
| Age Factors | 2 | 2014 | 1187 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2015 | 180 | 0.110 |
Why?
|
| Testosterone | 2 | 2010 | 47 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2016 | 345 | 0.110 |
Why?
|
| Antigens, CD | 1 | 2013 | 103 | 0.110 |
Why?
|
| Hemostatics | 1 | 2012 | 11 | 0.110 |
Why?
|
| Cholesterol, HDL | 3 | 2013 | 177 | 0.100 |
Why?
|
| Antifibrinolytic Agents | 1 | 2012 | 16 | 0.100 |
Why?
|
| Epoxide Hydrolases | 1 | 2012 | 4 | 0.100 |
Why?
|
| Genistein | 3 | 2007 | 14 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 155 | 0.100 |
Why?
|
| Histological Techniques | 1 | 2011 | 6 | 0.100 |
Why?
|
| Cell Aging | 1 | 2011 | 1 | 0.100 |
Why?
|
| Estrogen Receptor alpha | 4 | 2013 | 50 | 0.100 |
Why?
|
| Anatomy, Cross-Sectional | 2 | 2010 | 15 | 0.100 |
Why?
|
| Cytokines | 1 | 2013 | 259 | 0.100 |
Why?
|
| Coloring Agents | 1 | 2011 | 29 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 164 | 0.100 |
Why?
|
| Postoperative Care | 1 | 2011 | 76 | 0.090 |
Why?
|
| Stromal Cells | 1 | 2011 | 84 | 0.090 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 73 | 0.090 |
Why?
|
| Drug Therapy, Combination | 2 | 2008 | 284 | 0.090 |
Why?
|
| Hot Flashes | 2 | 2017 | 48 | 0.090 |
Why?
|
| Hierarchy, Social | 1 | 2010 | 24 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2011 | 115 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 899 | 0.090 |
Why?
|
| Chemokine CCL2 | 1 | 2010 | 48 | 0.090 |
Why?
|
| Antioxidants | 1 | 2011 | 114 | 0.090 |
Why?
|
| Pelvis | 1 | 2010 | 61 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2010 | 764 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2010 | 251 | 0.080 |
Why?
|
| Myositis | 1 | 2009 | 10 | 0.080 |
Why?
|
| Injections, Intraperitoneal | 1 | 2009 | 44 | 0.080 |
Why?
|
| Sexual Maturation | 1 | 2009 | 25 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2012 | 916 | 0.080 |
Why?
|
| Stress, Psychological | 1 | 2010 | 218 | 0.080 |
Why?
|
| Drug Stability | 1 | 2008 | 8 | 0.080 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2008 | 7 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 1527 | 0.080 |
Why?
|
| Risk | 2 | 2011 | 318 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2012 | 1824 | 0.080 |
Why?
|
| Rats | 2 | 2009 | 1586 | 0.070 |
Why?
|
| Aged | 3 | 2017 | 10288 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2017 | 3294 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 738 | 0.070 |
Why?
|
| Genitalia, Female | 1 | 2006 | 4 | 0.070 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2006 | 3 | 0.070 |
Why?
|
| Macaca | 2 | 2018 | 24 | 0.070 |
Why?
|
| Benzopyrans | 1 | 2006 | 5 | 0.070 |
Why?
|
| Oleic Acids | 1 | 2005 | 4 | 0.070 |
Why?
|
| Esters | 1 | 2005 | 10 | 0.070 |
Why?
|
| Anticarcinogenic Agents | 1 | 2006 | 23 | 0.070 |
Why?
|
| Research Design | 1 | 2008 | 310 | 0.070 |
Why?
|
| Blood Chemical Analysis | 1 | 2005 | 22 | 0.070 |
Why?
|
| Insulin | 2 | 2019 | 366 | 0.060 |
Why?
|
| Male | 5 | 2018 | 19091 | 0.060 |
Why?
|
| Adult | 2 | 2021 | 9327 | 0.060 |
Why?
|
| Feces | 2 | 2021 | 34 | 0.060 |
Why?
|
| Primary Prevention | 1 | 2005 | 54 | 0.060 |
Why?
|
| Follicular Phase | 2 | 2015 | 10 | 0.060 |
Why?
|
| Breast | 1 | 2004 | 61 | 0.060 |
Why?
|
| Hydrocortisone | 2 | 2017 | 57 | 0.060 |
Why?
|
| Contraceptive Agents, Female | 1 | 2003 | 15 | 0.060 |
Why?
|
| Plant Preparations | 1 | 2004 | 22 | 0.060 |
Why?
|
| Contraceptives, Oral | 1 | 2003 | 22 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2003 | 39 | 0.060 |
Why?
|
| Chromans | 1 | 2003 | 5 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2007 | 843 | 0.050 |
Why?
|
| Hormone Replacement Therapy | 1 | 2003 | 88 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2013 | 62 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 272 | 0.050 |
Why?
|
| Dietary Proteins | 2 | 2014 | 52 | 0.050 |
Why?
|
| Bacteroides | 1 | 2021 | 7 | 0.050 |
Why?
|
| Prevotella | 1 | 2021 | 8 | 0.050 |
Why?
|
| Lactobacillus | 1 | 2021 | 14 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 300 | 0.050 |
Why?
|
| Sex Factors | 1 | 2002 | 662 | 0.050 |
Why?
|
| T-Lymphocytes | 2 | 2013 | 124 | 0.040 |
Why?
|
| Cell Size | 1 | 2019 | 38 | 0.040 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2019 | 8 | 0.040 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2019 | 8 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2012 | 142 | 0.040 |
Why?
|
| Ventricular Remodeling | 1 | 2019 | 58 | 0.040 |
Why?
|
| Biopsy | 2 | 2012 | 260 | 0.040 |
Why?
|
| Species Specificity | 1 | 2019 | 87 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2005 | 2277 | 0.040 |
Why?
|
| Fibrosis | 1 | 2019 | 118 | 0.040 |
Why?
|
| Myocytes, Cardiac | 1 | 2019 | 86 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 192 | 0.040 |
Why?
|
| Social Class | 1 | 2019 | 88 | 0.040 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2018 | 13 | 0.040 |
Why?
|
| Radiation Dosage | 2 | 2010 | 81 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2018 | 97 | 0.040 |
Why?
|
| Peptide Hormones | 1 | 2018 | 11 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2018 | 94 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 240 | 0.040 |
Why?
|
| Anemia | 1 | 2018 | 59 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2018 | 70 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2018 | 104 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 104 | 0.040 |
Why?
|
| Estrone | 2 | 2008 | 7 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2018 | 121 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2018 | 173 | 0.040 |
Why?
|
| Myocardium | 1 | 2018 | 186 | 0.040 |
Why?
|
| Cortodoxone | 1 | 2017 | 1 | 0.040 |
Why?
|
| Hydroxyprogesterones | 1 | 2017 | 4 | 0.040 |
Why?
|
| Corticosterone | 1 | 2017 | 7 | 0.040 |
Why?
|
| Reference Values | 1 | 2017 | 247 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 874 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2018 | 444 | 0.040 |
Why?
|
| Fertility | 1 | 2017 | 31 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2017 | 461 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 979 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2019 | 461 | 0.030 |
Why?
|
| Carbohydrate Metabolism | 1 | 2016 | 15 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2016 | 10 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2016 | 10 | 0.030 |
Why?
|
| Elastin | 1 | 2016 | 14 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 21 | 0.030 |
Why?
|
| Frozen Sections | 1 | 2016 | 18 | 0.030 |
Why?
|
| Ovulation | 1 | 2015 | 9 | 0.030 |
Why?
|
| Menopause, Premature | 1 | 2015 | 9 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 635 | 0.030 |
Why?
|
| Triiodothyronine | 1 | 2014 | 7 | 0.030 |
Why?
|
| Thyrotropin | 1 | 2014 | 8 | 0.030 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2015 | 108 | 0.030 |
Why?
|
| Thyroxine | 1 | 2014 | 16 | 0.030 |
Why?
|
| Thyroid Gland | 1 | 2014 | 15 | 0.030 |
Why?
|
| Collagen | 1 | 2016 | 225 | 0.030 |
Why?
|
| Somatomedins | 1 | 2014 | 5 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2005 | 181 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2014 | 45 | 0.030 |
Why?
|
| Luteal Phase | 1 | 2013 | 28 | 0.030 |
Why?
|
| Endometrial Hyperplasia | 1 | 2013 | 14 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 161 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2013 | 30 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2013 | 42 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 26 | 0.030 |
Why?
|
| Disease Progression | 1 | 2015 | 593 | 0.030 |
Why?
|
| RNA | 1 | 2013 | 91 | 0.030 |
Why?
|
| Mice | 1 | 2018 | 2476 | 0.030 |
Why?
|
| Phenylurea Compounds | 1 | 2012 | 10 | 0.030 |
Why?
|
| Cytosol | 1 | 2012 | 25 | 0.030 |
Why?
|
| Eicosanoids | 1 | 2012 | 8 | 0.030 |
Why?
|
| Urea | 1 | 2012 | 37 | 0.030 |
Why?
|
| Phospholipases A2 | 1 | 2011 | 20 | 0.030 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2011 | 8 | 0.030 |
Why?
|
| Claudins | 1 | 2011 | 8 | 0.030 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2011 | 27 | 0.020 |
Why?
|
| Cadherins | 1 | 2011 | 26 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2011 | 44 | 0.020 |
Why?
|
| Macrophages | 1 | 2013 | 192 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 97 | 0.020 |
Why?
|
| Analgesics | 1 | 2012 | 109 | 0.020 |
Why?
|
| Piperidines | 1 | 2012 | 117 | 0.020 |
Why?
|
| Menstruation Disturbances | 1 | 2010 | 3 | 0.020 |
Why?
|
| Anovulation | 1 | 2010 | 5 | 0.020 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2010 | 22 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2010 | 44 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 1424 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2010 | 201 | 0.020 |
Why?
|
| Organ Size | 1 | 2010 | 208 | 0.020 |
Why?
|
| Contrast Media | 1 | 2010 | 138 | 0.020 |
Why?
|
| P-Selectin | 1 | 2008 | 10 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 17 | 0.020 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2008 | 14 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 351 | 0.020 |
Why?
|
| Liver | 1 | 2012 | 482 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2008 | 41 | 0.020 |
Why?
|
| Social Dominance | 1 | 2008 | 18 | 0.020 |
Why?
|
| Compliance | 1 | 2007 | 13 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2007 | 26 | 0.020 |
Why?
|
| Radiographic Image Enhancement | 1 | 2007 | 26 | 0.020 |
Why?
|
| Radiometry | 1 | 2007 | 39 | 0.020 |
Why?
|
| Intestines | 1 | 2007 | 61 | 0.020 |
Why?
|
| Bacteria | 1 | 2007 | 46 | 0.020 |
Why?
|
| Laboratory Animal Science | 1 | 2006 | 1 | 0.020 |
Why?
|
| Animal Nutritional Physiological Phenomena | 1 | 2006 | 9 | 0.020 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2006 | 10 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2007 | 523 | 0.020 |
Why?
|
| Uterine Neoplasms | 1 | 2006 | 26 | 0.020 |
Why?
|
| Pterocarpans | 1 | 2006 | 4 | 0.020 |
Why?
|
| Fluoroimmunoassay | 1 | 2005 | 2 | 0.020 |
Why?
|
| Hysterectomy | 1 | 2006 | 45 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2005 | 35 | 0.020 |
Why?
|
| Vagina | 1 | 2006 | 57 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2006 | 63 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 259 | 0.020 |
Why?
|
| Uterus | 1 | 2006 | 93 | 0.020 |
Why?
|
| Biological Availability | 1 | 2004 | 21 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2004 | 25 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 589 | 0.010 |
Why?
|
| Kanamycin | 1 | 2003 | 1 | 0.010 |
Why?
|
| Vancomycin | 1 | 2003 | 20 | 0.010 |
Why?
|
| Metronidazole | 1 | 2003 | 14 | 0.010 |
Why?
|
| Doxycycline | 1 | 2003 | 25 | 0.010 |
Why?
|
| Mesocricetus | 1 | 2002 | 3 | 0.010 |
Why?
|
| Cricetinae | 1 | 2002 | 39 | 0.010 |
Why?
|